



DRUG DISCOVERY 2023

DIVERSE THINKING -
NEW PERSPECTIVES

18 - 19 OCTOBER 2023

ACC EXHIBITION CENTRE, LIVERPOOL



#ELRIG

#ELRIGDD23

#DRUGDISCOVERY

 elrig.org

 [@ELRIG_UK](https://twitter.com/ELRIG_UK)

 [elrig](https://www.linkedin.com/company/elrig)

 [elrig_uk](https://www.instagram.com/elrig_uk)

WELCOME TO DRUG DISCOVERY 2023

A MESSAGE FROM THE CHAIR OF ELRIG, MELANIE LEVERIDGE



On behalf of ELRIG I would like to welcome you to the 17th Drug Discovery meeting, Drug Discovery 2023.

The Drug Discovery conference is the flagship of all ELRIG events and marks the pinnacle of the ELRIG yearly meetings calendar, by bringing together the drug discovery life science community, for a festival of cutting-edge science and technology. I am delighted that we can come together at Drug Discovery 2023 – ELRIG's biggest event to date!

This year's theme of "Diverse Thinking – New Perspectives" challenges both ELRIG and the wider community to take a look with fresh eyes and an open mind to tackle the major challenges in human health. ELRIG's strategic pillars are the foundation for the provision of an impressive scientific programme which is free-of-charge to attend.

There are numerous highlights that we will announce at the meeting, during my introduction, I will talk about ELRIG's success in the year as well as our full calendar of events for 2024 so you can save the dates.

We welcome two fantastic plenary keynote speakers, Professor Prof Janet Hemingway CBE, FRS, Founding Director of Infection Innovation Consortium (iiCON), and Dr Dave Powell, Chief Scientific Officer (CSO) of LifeArc. A full programme of talks and workshops in the Tech Theatre, automation and robotics on day one and sustainability on day two. The Learning Zone with activities for the Early Careers Professionals including deliberate action on inclusivity and diversity with mentorship and careers focus with advice and the famous "Network like a boss"

We welcome our partner organisations, the British Pharmacological Society (BPS), Cancer Research

Horizons, My Green Lab, the Royal Society of Chemistry (RSC), The Society for Lab Automation and Screening (SLAS) and SiLA, who have all contributed to the programme this year.

We are delighted to be presenting the following awards, ELRIG's Impact Award, ELRIG's Life time achievement Award and four poster awards.

As you can see there is lots going on and it promises to be a fantastic two days. The success of ELRIG is dependent upon the many volunteers who give their time freely to create our meetings and other events as well as the vendor community who support our organisation, by taking sponsorship opportunities at each meeting. I would like to thank the conference directors, track chairs, speakers, and exhibitors for their contributions to this event. The volunteers and vendors are supported by an outstanding ELRIG professional team.

Finally, I would like to thank you for attending and I look forward to re-connecting with you all.

Enjoy the meeting!

AWARDS AT DRUG DISCOVERY 2023

ELRIG OUTSTANDING ACHIEVEMENT AWARD WINNER

Katy Kettleborough, [LifeArc](#)

Working in the Translational space: a career in bridge building

Wednesday 18 October 09.20

ELRIG EARLY CAREER PROFESSIONAL IMPACT AWARD WINNER

Restuan Lubis, [Lead Discovery Center GmbH](#)

HTS-Screening technology platform: Helicase inhibitors

Thursday 19 October 09.55

DRUG TARGET REVIEW - DRUG DISCOVERY ARTICLE COMPETITION WINNER

Rosa Woldegebriel, [Microsang Ltd](#)

Thursday 19 October 10.15





Alex Alderton
Senior Director of High Throughput
Screening
AstraZeneca



Katie Chapman
Head of Discovery Biology,
VC funded Biotech Company



Laura Eghobamien,
Founder
Black Medical Scientific Network



Jon Hutchinson
Scientific Leader,
GSK



Simon Ward
Director of the Medicines Institute,
Cardiff University

AS CONFERENCE DIRECTORS IT IS OUR GREAT PLEASURE TO WELCOME YOU TO LIVERPOOL FOR DRUG DISCOVERY 2023!

This year's theme "Diverse Thinking – New Perspectives" was chosen to challenge us all to revisit the how and the why of drug discovery by providing a platform for the whole drug discovery community to meet at Europe's largest free-to-attend life science event.

2023 is the largest ever ELRIG Drug Discovery meeting and attendees will be able to:

- Listen to over 50 world-class speakers and almost 40 technology presentations.
- Read and discuss over 200 cutting-edge scientific posters.
- Visit over 160 exhibitors, who will display their latest and most innovative technologies in the exhibition hall.

Our organising committee and track chairs have been working hard since late 2022 and thanks to them we have again been able to assemble a world-class lineup of scientific speakers, with almost 100 talks taking place across 11 tracks. We encourage you to engage in as much of the science as you possibly can and to take full advantage of the exhibitors' expertise and knowledge to enhance your own research. The support of the scientific

vendors of ELRIG ensure that these conferences are free to attend, so please show your appreciation by visiting the exhibition hall, talking to the vendors and learning more about the technologies available. Networking is a valuable part of any event, so don't be shy and say 'Hi', some of the best conversations happen in the coffee queue and for our Early Careers Professionals there are some great talks to help your careers in the Learning Zone.

We would like to thank the ELRIG Board and General Committee for their support in assembling this worldclass scientific programme. We would also like to thank the ELRIG Operational Team, for patiently shepherding us and the Track Chairs through the organising process. Without their help, together with all the other volunteers, this meeting would not be possible. Finally, this meeting would be nothing without you, the meeting delegate. We thank you in advance for your participation and look forward to connecting with you over the next couple of days. As always, we welcome your feedback on how we can further improve the agenda to ensure the growth and success of ELRIG's Drug Discovery conference for the future.

EQUALITY, DIVERSITY AND INCLUSIVITY - DELIBERATE ACTION TO EFFECT CHANGE

ELRIG intends that its events are fully representative of the community it serves and has introduced guidelines for the recruitment and involvement of programme speakers and is monitoring participation and representation at all activities and events.

ELRIG is also promoting good practice among the partner and vendors organisations it works with.

PROGRAMME AT A GLANCE

DAY 1	AUDITORIUM 1	AUDITORIUM 2	AUDITORIUM 3	AUDITORIUM 4	ELRIG TECH THEATRE	THE VIEWING TERRACE	LEARNING ZONE
08.00-09.00	Registration						Early Career Professional Meet & Greet
09.00-10.20	Conference Welcome, ELRIG Yearly Report, ELRIG Outstanding Achievement Award & Keynote Talk - Janet Hemingway, Liverpool School Of Tropical Medicine in Auditorium 1						
10.20-11.05	Refreshment Break				Charles River Laboratories presents All you need are hits!	Refreshment Break	Science Solutions presents Nanopharm: Inhalation product development and careers within
11.05-12.45	Cellular Technologies for Drug Discovery	Transforming Cancer Drug Discovery - supported by Cancer Research Horizons	Delving into the diversity of chemistry, driving molecules from concept to clinic	Augmenting R&D with AI	Robotics and Automation: Supporting Collaborative Science - supported by SILA	Drug development and drug repurposing: strategies for enhancing success rates - supported by the British Pharmacological Society	
12.45-14.00	Refreshment Break						Early Career Professional Flash Poster Presentations
14.00-15.15	Cellular Technologies for Drug Discovery	Transforming Cancer Drug Discovery - supported by Cancer Research Horizons	Delving into the diversity of chemistry, driving molecules from concept to clinic	Augmenting R&D with AI	Robotics and Automation: Supporting Collaborative Science - supported by SILA	Drug development and drug repurposing: strategies for enhancing success rates - supported by the British Pharmacological Society	
15.15-15.45	Refreshment Break						The power of mentorship – why representation matters! - Afro - Caribbean Commercial Science Network
15.45-17.00	Cellular Technologies for Drug Discovery	Transforming Cancer Drug Discovery - supported by Cancer Research Horizons	Delving into the diversity of chemistry, driving molecules from concept to clinic	Augmenting R&D with AI	Robotics and Automation: Supporting Collaborative Science - supported by SILA	Drug development and drug repurposing: strategies for enhancing success rates - supported by the British Pharmacological Society	
17.00-19.00	Networking with poster session, in the Exhibition Hall						Network like a Boss 17.15-18.15

Exhibition Hall open from 08.00 to 19.00

DAY 2	AUDITORIUM 1	AUDITORIUM 2	AUDITORIUM 3	AUDITORIUM 4	ELRIG TECH THEATRE	LEARNING ZONE
07.15-08.45	Drug Target Review Breakfast Meeting - Advancing next generation precision medicine: innovations in biospecimen collection and analysis for enhanced quality control in Upper Floor Room 23					
08.00-09.00	Registration					Early Career Professional Meet & Greet
09.00-10.15	Keynote talk - Dave Powell, LifeArc ECP Impact Award, Poster winners & Drug Target Review winner in Auditorium 1					
10.15-11.00	Refreshment Break				Hitchhiker's Guide to Accelerated Drug Discovery with AI - Join our humble effort to make a big impact in the industry!	Science Solutions presents Transition Bio: Use of microfluidics for the primary screening of condensates
11.00-12.50	Hit identification and screening - supported by SLAS	Translating ideas into therapies	Biopharmaceutical discovery	Chemistry enabling drug discovery from start to clinic - supported by the Royal Society of Chemistry	Sustainability: from bench to bedside and beyond	How marketing and sales professionals can utilise AI tools to drive better results - Vendor exhibition ticket holders only
12.50-14.00	Refreshment Break with poster session at 13.00-14.00				Talking TechBio: Breaking The Ice - Listen to the science behind four young TechBio companies followed by a Q&A session to find out how they moved from idea to commercial reality	Early Career Professional Flash Poster Presentations
14.00-15.15	Hit identification and screening - supported by SLAS	Translating ideas into therapies	Biopharmaceutical discovery	Chemistry enabling drug discovery from start to clinic - supported by the Royal Society of Chemistry	Sustainability: from bench to bedside and beyond	
15.15-15.45	Refreshment Break					
15.45-17.00	Hit identification and screening - supported by SLAS	Translating ideas into therapies	Biopharmaceutical discovery	Chemistry enabling drug discovery from start to clinic - supported by the Royal Society of Chemistry	Sustainability: from bench to bedside and beyond	

Exhibition Hall open from 08.00 to 15.45

 Scientific Conference Talks

 Early Career Professional Activities

INFORMATION FOR PARTICIPANTS

To help keep DRUG DISCOVERY 2023 a safe space, we require the following from all attendees:

Pre-registration for the meeting is essential. At ELRIG we want all our meeting participants to enjoy, participate in and contribute to the event.

ELRIG does not accept harassment or intimidation of ELRIG participants in any form whether verbal, physical, or written (including on social media or by email).

Harassment includes, but is not limited to:

1. Offensive or unwanted conduct on the basis of age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, sex or sexual orientation which has the purpose or effect of violating dignity or creating an intimidating, hostile or degrading environment.
2. Use of sexualised or other inappropriate images or unwelcome sexualised content, inappropriate physical contact, unwelcome sexual attention or stalking.
3. Sustained interruption of speakers or those asking questions.
4. Unwanted photography or filming.

Intimidation includes, but is not limited to:

1. Making threats.
2. Bullying.
3. Personal attacks.

Participants who do not adhere to these rules will be asked to stop and expected to comply immediately. Participants may be removed from any meeting at the discretion of ELRIG's management. If you are being harassed/intimidated, notice that someone else is being harassed/intimidated, or have any other concerns, please contact any of the ELRIG management team immediately. They will be able to step in to remove you or others from a chain of communication, if this is the preferred action, and can also facilitate a discussion or mediation. If you wish, you may also nominate someone else to support facilitating any mediation or as an observer to this process.

WIFI

Wi-Fi is freely available throughout the venue and may be found by following the below instructions:

1. Enable the wireless function on your device
2. Connect to the Free_Wifi SSID (wireless network)
3. Your device should automatically prompt you to sign into the network, if it does not or you miss the notification, browse to a web site of your choice e.g. accliverpool.com
4. You will be re-directed to the ACC Liverpool Landing Page
5. Click on the 'FREE WI-FI ACCESS' button
6. The page of your choice will then load.

PRAYER ROOM

Prayer Room is UF18, located on the upper level

QUIET ROOM

Quiet room is UF19, located on the upper level

FAMILY ROOM

Family room is UF24, located on the upper level. Toilets with baby change facilities are next door.

ACCESSIBLE PARKING

Accessible Parking is found at the adjacent King's Dock Car Park, with spaces spread over seven floors.

DISABLED TOILETS

Disabled toilets can be found on the atrium level, in the Exhibition Hall and on the upper level.

WATER REFILL STATIONS

Water refill stations are located in the Exhibition Hall.

CLOAKROOMS

The cloakrooms are found in the atrium and are free to use. The cloakrooms are open during the open hours of the conference.

ELRIG MOBILE APP

Download the free ELRIG app and access all our conference information, programme and more from your phone or tablet.

- View the event programme
- View presentation and poster abstracts
- View speaker profiles
- View the exhibitor guide
- View the delegate and exhibitor list
- Organise your day with your own favourites list
- Share your profile as vCard and QR Code and scan exhibitor QR code information tags
- Network – contact delegates, other exhibitors and speakers easily through opt-in directories and integration with Linked-In, Twitter and Facebook

Download our Drug Discovery App... search for and install The Event App by EventsAir onto your mobile device, then use the Event App Code found in your email. For convenience, you can add the app to your device's home screen.




ELRIG volunteer staff are wearing distinctive red t-shirts. If you need help on any issue, ask a Red-Shirt!

ELRIG HUB

Located in the middle of the Exhibition Hall, the ELRIG Hub is a place to meet the ELRIG operational team for a coffee, find out more about how ELRIG works, our governance and perhaps you may be inspired to volunteer.

Find out about events in 2024 whether you are a delegate wishing to attend or a scientific vendor wishing to exhibit, we will have information on the conferences, forums and networking events for your 2024 calendar.



ELRIG AREA

ELRIG'S EQUALITY DIVERSITY AND INCLUSION (EDI) AIMS AND GUIDING PRINCIPLES

- ELRIG will communicate the journey it has started and the conclusions that it comes to.
- The process and implementation of outcomes will be transparent.
- Data will guide action.
- Mechanisms will be put in place to ensure that accessibility is maximised at all events.
- Rather than setting a series of targets, this will be a cultural change, both for ELRIG and its community.
- Rather than a policy we will have a set of guiding principles.
- Guiding principles will be embedded in governance and all Work Groups daily activities.

We will promote equality, by welcoming all to all our events and will be inclusive, by ensuring all are able to attend and that our events will represent the diversity of our community.

OUR EQUALITY PRINCIPLE IS: We will ensure all are welcome, by profiling the demographics of attendees by segment, geography, age, ethnicity, disability and gender, monitoring and ensuring that no one group is favoured nor excluded and acting to ensure equal outcomes and opportunities for the entire ELRIG community.

OUR INCLUSIVITY PRINCIPLE IS: We will ensure that accessibility is maximised at all events, by removing barriers to those with disabilities, limits on finances, have caring and parental responsibilities, religious needs and are safe spaces to collaborate within. To ensure our principles remain relevant, we will solicit, monitor and act upon relevant feedback during and after events.

OUR DIVERSITY PRINCIPLE IS: We will ensure that our events are attended by at least 50% from the UK and 50% from the ROW, that there is a gender balance at our events, by ensuring that the diversity mix of our speakers represents the diversity of our delegates, and that the diversity mix of our delegates represents the diversity of the community, as well as ensuring that scientific content reflects the diversity of our community.

DAY 1 - 18 OCTOBER - AUDITORIUM 1

CELLULAR TECHNOLOGIES FOR DRUG DISCOVERY

18 October 2023
Auditorium 1

TRACK CHAIRS



Charlotte Beaver
Wellcome Sanger Institute



Sapna Desai
GSK

Cellular technologies encompass a wide range of critical tools used throughout the drug discovery process. Continued drive from industry and academia to strive for increasingly complex cellular microenvironments to better mimic in vivo conditions has led to rapid advancement in the use of 3D cell culture models, stem cells and

functional genomics techniques to supplement more traditional recombinant cellular-based approaches. This session highlights innovative approaches taken by researchers using cellular technologies as a powerful tool to understand disease mechanism, identify novel targets and assess potential drug candidates.

08.00-09.00	Registration
09.00-09.20	ELRIG Annual Review
09.20-09.30	ELRIG Outstanding Achievement Award Presentation
09.30-09.35	Conference Welcome & Keynote Introduction
09.35-10.20	Plenary Keynote - iiCON: taking infection therapeutics from hits to leads - Janet Hemingway, iiCON
10.20-11.00	Refreshment Break
11.00-11.10	Track Chair Introduction - Charlotte Beaver, Wellcome Sanger Institute and Sapna Desai, GSK
11.10-11.40	A view from the axon side: investigating neuronal function and RNA biology in health and disease using compartmentalised microfluidic culture systems - Fredrico Dajas-Bailador, University of Nottingham
11.40-12.10	Conference Partner Presentation - Yokogawa Deutschland GmbH
12.10-12.40	Developing an experimental platform for functional and transcriptomic analysis of neurodegenerative disease genes - Caia Dominicus, Wellcome Sanger Institute
12.40-12.45	Technology Spotlight - Promega
12.45-14.00	Refreshment Break
14.00-14.30	Combined approaches to CxG and FxG screening in Treg cells using multi-panel flow cytometry for inflammation - Nazia Parvez, GSK
14.30-14.40	Technology Spotlight Sponsorship
14.40-15.10	TBC
15.10-15.45	Refreshment Break
15.45-16.15	Stromal Regulation of Patient-Derived Organoid Drug Responses - Maria Ramos Zapeatero, ETH
16.15-16.30	Industry Insider - Nanolive
16.30-17.00	Humanized in vitro bone marrow microphysiological system enables clinical haematotoxicity predictions of oncology drug combinations - Natacha Bohin, AstraZeneca
17.00-19.00	Networking in The Exhibition Hall / Network like a boss 17.00 - 18.30

DAY 1 - 18 OCTOBER - AUDITORIUM 2

TRANSFORMING CANCER DRUG DISCOVERY

SUPPORTED BY CANCER RESEARCH HORIZONS



18 October 2023
Auditorium 2

TRACK CHAIRS



Stuart Farrow
Cancer Research Horizons



Emma Carswell
Cancer Research Horizons

The oncology therapeutic landscape has been transformed in recent years through the advent of immunotherapy, which has in turn catalysed investment into new and diverse drug discovery approaches. These range from innovative target discovery through bioinformatic analysis of clinical datasets through to significant advances

in medicinal chemistry that have brought previously “undruggable” targets into focus. Creative and flexible partnerships with the biotech and pharma industries are also playing a critical role in progressing novel medicines into the clinical setting. This session will showcase cutting edge insights into these exciting areas.

08.00-09.00	Registration
09.00-10.20	All Content Streamed from Auditorium 1
10.20-11.00	Refreshment Break
11.00-11.10	Track Chair Introduction - Stuart Farrow, Cancer Research Horizon, & Emma Carswell, Cancer Research Horizons
11.10-11.40	Immuno-oncology therapeutic discovery via reverse translation in the multiomic machine learning era - Kevin Litchfield, University College London
11.40-12.10	Conference Partner Presentation - Lightcast
12.10-12.40	NUDELs – the synthesis of fragment based and DNA-encoded lead generation - Mike Waring, Newcastle University
12.40-12.45	Technology Spotlight - MD Catapult
12.45-14.00	Refreshment Break
14.00-14.30	Introducing DragonFold: A Deep Learning Protein-Ligand Co-Folding Platform - Sarah Skerrat, Charm Therapeutics
14.30-14.35	Technology Spotlight - Abcam
14.35-14.40	Technology Spotlight - Semarion
14.40-15.10	It's Degrading... Targeted Protein Degradation for Cancer Drug Discovery - Kirsten McAulay, University of Dundee
15.10-15.45	Refreshment Break
15.45-16.15	Reviving the PI3K δ space: Roginolisib paves the way to safely target PI3Kd in solid and haematologic tumors - Giusy Di Conza, iOnctura
16.15-16.30	Industry Insider - Oxford Nanopore Technologies
16.30-17.00	Audience Lead Panel Discussion with Q&A
17.00-19.00	Networking in The Exhibition Hall / Network like a boss 17.00 - 18.30

DAY 1 - 18 OCTOBER - AUDITORIUM 3

DELVING INTO THE DIVERSITY OF CHEMISTRY, DRIVING MOLECULES FROM CONCEPT TO CLINIC

18 October 2023
Auditorium 3

TRACK CHAIRS



Allan Jordan
Sygnature Discovery



Beth Thomas
Storm Therapeutics

Chemistry makes a pivotal and essential contribution to the delivery of a diverse range of novel human therapeutics and modalities. These diverse contributions are underpinned by a wider diversity, from the range of specialisms engaged, the scope of methodologies

employed, and the skills, experiences and backgrounds of the practitioners involved. This session aims to celebrate some aspects of that diversity, showcasing forefront science from across the chemical community.

08.00-09.00	Registration
09.00-10.20	All Content Streamed from Auditorium 1
10.20-11.00	Refreshment Break
11.00-11.10	Track Chair Introduction - Allan Jordan, Sygnature Discovery & Beth Thomas, Storm Therapeutics
11.10-11.40	Biocatalysis as an Enabling Technology in Sustainable Pharmaceutical Synthesis and Drug Discovery - Godwin Aleku, Institute of Pharmaceutical Science, King's College London
11.40-12.10	Conference Partner Presentation - WuXi AppTec
12.10-12.40	Novel synthetic approaches for the next-generation therapeutics - Sona Krajcovicova, University of Cambridge
12.40-12.45	Technology Spotlight - Scale
12.45-14.00	Refreshment Break
14.00-14.30	Iterative Cyclization Cascades for Organic Synthesis - Alison Frontier, University Of Rochester
14.30-14.45	Industry Insider - Horiba
14.45-15.05	Build-Couple-Transform: A new paradigm for late-stage transformations for efficient library synthesis - Hannah Stewart, Newcastle University
15.05-15.15	Technology Spotlight - George Ballantyne, Evotec
15.10-15.45	Refreshment Break
15.45-16.15	Journey to the centre of the junction: Supramolecular inorganic DNA junction binders - James Craig, University of Birmingham
16.15-16.20	Technology Spotlight
16.20-16.40	Varied syntheses of chemical probes for TRPC5 channels - Aiden Johnson, University of Leeds
16.40-17.00	Cytotoxic Ag-NHC complexes as lactate dehydrogenase inhibitors - Sam Walsworth, University of Huddersfield
17.00-19.00	Networking in The Exhibition Hall / Network like a boss 17.00 - 18.30

DAY 1 - 18 OCTOBER - AUDITORIUM 4

AUGMENTING R&D WITH AI

18 October 2023
Auditorium 4

TRACK CHAIRS



Lee Larcombe
APEXOMIC



Charlotte Deane
University of Oxford

Advances in technology means that we generate much more data about biological systems and the complexities of disease as we search for new medicines. It is becoming increasingly clear that not only do we need teams and communities of expert scientists, but enhanced data

analytic tools to support those scientists in extracting knowledge from data that can be used guide research. This track will explore how AI can be used to augment the R&D process and address challenges in target discovery, drug design and product development.

08.00-09.00	Registration
09.00-10.20	All Content Streamed from Auditorium 1
10.20-11.00	Refreshment Break
11.00-11.10	Track Chair Introduction - Lee Larcombe, Apexomic & Charlotte Deane, University of Oxford
11.10-11.40	Hidden in plain sight - ophthalmic data for disease-agnostic augmentation of drug discovery R&D with AI - Wen Hwa Lee, Action Against AMD
11.40-12.10	Industry Insider - Synthace
12.10-12.40	Turning science into medicine: Digital, computational and ML tools for biologic molecule design - Andrew Buchannan, AstraZeneca
12.40-12.45	Technology Spotlight - Benchling
12.45-14.00	Refreshment Break
14.00-14.30	Inverse folding for antibody sequence design using deep learning - Constantin Schneider, Exscientia
14.30-14.35	Technology Spotlight - Nuclera
14.35-14.40	Technology Spotlight
14.40-15.10	TBC - Lindsay Edwards, Relation Therapeutics
15.10-15.45	Refreshment Break
15.45-16.15	Harnessing AI for R&D in Drug Discovery - Thomas Bridge, Intellegens
16.15-16.30	Industry Insider - Selvita
16.30-17.00	Skills for augmenting R&D with AI - Lee Larcombe, APEXOMIC
17.00-19.00	Networking in The Exhibition Hall / Network like a boss 17.00 - 18.30

DAY 1 - 18 OCTOBER - THE VIEWING TERRACE

DRUG DEVELOPMENT AND DRUG REPURPOSING: STRATEGIES FOR ENHANCING SUCCESS RATES

SUPPORTED BY BRITISH PHARMACOLOGICAL SOCIETY AND UKPGx



18 October 2023
The Viewing Terrace

TRACK CHAIRS



Munir Pirmohamed
British Pharmacological Society



Drug discovery and development is a risky and costly business. The overall failure rate is >96%, and the estimated cost of bringing one drug to market is ~\$1.3 billion. Newer approaches such as artificial intelligence and proteogenomics can improve success rates, both for new drug development

and for drug repurposing. The symposium will look at the technologies which are being used by industry and academia to improve success rates and identify new drug repurposing opportunities.

10.20-11.00	Refreshment break
11.00-11.10	Track Chair Introduction Munir Pirohamed
11.10-11.40	TBC - Richard Turner, GSK
11.40-12.10	Genomics for drug discovery and development: An AstraZeneca perspective – Katherine Smith, AstraZeneca
12.10-12.25	Industry Insider - BGI Tech Solutions
12.25-12.55	Drug target identification and validation within the Open Targets consortium – Panos Zalmas, Open Targets / Sanger Institute
12.55-14.00	Refreshment Break
14.00-14.30	Evolution of genomics in drug discovery - converging to causality – David Michalovich, Consultant
14.30-15.00	Proteogenomic approaches for drug target discovery and repurposing – Maik Pietzner, Charité Berlin
15.00-15.30	Refreshment break
15.30-16.00	Known knowns to unknown unknowns – Network analysis of the repurposome – David Cavalla, Numedicus Ltd
16.00-17.00	Sir James Black Award Winner
17.00-19.00	Networking in The Exhibition Hall/Network like a boss 17.00 - 18.30

DAY 1 - 18 OCTOBER - TECH THEATRE

ROBOTICS AND AUTOMATION: SUPPORTING COLLABORATIVE SCIENCE – HOW USING THE RIGHT TOOLS ENABLES SCIENTISTS TO DISCOVER BETTER DRUGS FASTER



SUPPORTED BY SiLA

18 October 2023
Tech Theatre

TRACK CHAIRS



Lorna Suckling
GSK



Burkhard Schaefer
Splashlake



Patrick Courtney
SiLA

SPONSORED BY



Robotics and Automation remain essential technologies to accelerate science. The multiwell plate format has served us well and recent advances enable scientists to take automation to new levels. At the same time data has only become more important to organisations as well as

to scientists, calling for an infrastructure and tools they can rely upon. The format will be 3 short talks followed by a moderated panel with time given over to audience exchange.

08.00-09.00	Registration
09.00-10.20	All Content Streamed from Auditorium 1
10.20-11.00	Refreshment Break including All you need are hits! - Zack Gurard-Levin, Charles River Laboratories (10.30-10.45)
11.00-11.05	Track Chair Introduction – Robotics in the lab - Lorna Suckling, GSK
11.05-11.30	Towards new age of materials discovery using robotics and AI - Hatem Fakhruideen, University of Liverpool
11.30-11.50	Synthetic biology and automation for a greener future - James Johnson, Epoch Bioscience
11.50-12.10	Digitised drug discovery - Exploiting precision automation in the quest for reproducibility - Daniel Thomas, Actoris
12.10-12.45	Panel Discussion
12.45-14.00	Refreshment Break
14.00-14.05	Track Chair Introduction – Automating workflows – Patrick Courtney, SiLA
14.05-14.25	Integrating mobile robotics in life science laboratories - strategies and challenges - Kerstin Thurow, University of Rostock
14.25-14.45	Talk to all your robots at once! A beginner Python conceptual framework - Nessa Carson, AstraZeneca
14.45-15.10	Track Chair Introduction – Data in the lab - Burkhard Schaefer, Splashlake
15.10-15.45	Refreshment Break
15.45-15.50	Data in the lab - welcome - Burkhard Schaefer, AnIML
15.50-16.10	Driving Unilever's lab of the future using open standards - Andy Mitchell, Unilever
16.10-16.30	TBC
16.30-17.00	Panel Discussion
17.00-19.00	Networking in The Exhibition Hall / Network like a boss 17.00 - 18.30

DAY 1 - 18 OCTOBER - LEARNING ZONE

EARLY CAREER PROFESSIONALS (ECP)

18 October 2023
Learning Zone

The Learning Zone is a dedicated space for our Early Career Professionals (ECP), with sessions to aid networking, career progression, flash poster presentations and the popular 'Network Like A Boss' speed networking. If it's your first big conference (or you like pastries!), join us at our morning Meet & Greet sessions from 8am to meet with the ELRIG ECP workgroup and your fellow delegates.

08.00-09.00	Early Career Professionals: Breakfast Meet & Greet
09.00-10.20	Auditorium content only
10.30-11.00	Science Solutions presents Nanopharm: Inhalation product development and careers
11.05-12.45	Auditorium content only
12.45-14.00	Early Career Professional Flash Poster Presentations
14.00-17.00	Auditorium content only
15.20-15.40	The power of mentorship – why representation matters! - Daniel Similaki, Amina Osman Hassan and Camille Linsley, Afro Caribbean Commercial Science Network
15.45-17.00	Auditorium content only
17.00-18.30	Network like a boss!

We would like to extend our thanks to our fantastic group of 'bosses' taking part in NETWORK LIKE A BOSS!

Daniel Similaki – Founder of Afro Caribbean Commercial Science Network (ACCSN)

Daniel Anderson – CSO of Eikon Therapeutics

Paul Workman - Harrap Professor of Pharmacology and Therapeutics at The Institute of Cancer Research

Steve Rees – VP Discovery Biology at AstraZeneca

Richard Eglon – Senior Advisor at Arsenal Capital

Kelly Chibale – Professor at University of Cape Town

Martin Baron – Senior Lecturer at University of Manchester

Alison Rawlinson – Head of Marketing at Qkine Biotechnology

Katie Chapman – Head of Discovery Biology at TessellateBio

Nicola Hellen – In Vitro Team Director at RxCelerate Ltd

Zahra Jawad – CEO Founder of Creasallis

Nicola Caldwell - Medicinal Chemistry Team Leader, Drug Discovery Unit, University of Dundee

Jonathan Large – Scientific Director, Chemical Biology at Lifearc

Lee Larcombe – Founder and CEO at Apexomic

Sian Lewis – Associate Principal Scientist at MSD

Michael Kenny – Business Development Manager at AM Technology

Amos Fatokun - Professor of Pharmacology and Neuroscience at Liverpool John Moores University

Kelly Gray – Director, Open Innovation at AstraZeneca

Laura Eghobamien – Founder of Black Medical Scientific Network (BMSN)

Ian Waddell – CEO at Nodus Oncology

Sapna Desai - Group Leader, Screening Profiling & Mechanistic Biology at GSK

Michael Howell – Head of High Throughput Screening at The Francis Crick Institute

DAY 2 - 19 OCTOBER - AUDITORIUM 1

HIT IDENTIFICATION AND SCREENING

SUPPORTED BY SLAS



19 October 2023
Auditorium 1

TRACK CHAIRS



Carien Dekker
Novartis



Magda Otrocka
Ardigen

SPONSORED BY



The identification of high quality, well validated hit compounds is a crucial step in giving a drug discovery project the best chance of producing a successful medicine. The design of screening campaigns and the technologies selected are important factors in the success of these hit identification activities and are the

focus of this session. In this track you will hear about different techniques that can be applied to identify biologically active hit molecules and on recent innovations in this area. The presented methods will range from fragment based and DNA-encoded libraries to high throughput screening approaches.

08.00-09.00	Registration
09.00-09.05	Conference Director Welcome & Keynote Introduction
09.05-09.50	Plenary Keynote - The AMR Therapeutic Landscape and Reasons to Believe - Dave Powell, LifeArc
09.50-09.55	Early Career Professional Impact Award Introduction
09.55-10.15	ELRIG Early Career Professional Impact Award
10.15-10.20	Awards Presentation
10.20-11.00	Refreshment Break
11.00-11.05	Track Chair Introduction - Carien Dekker, Novartis Institute for Biomedical Research and Magdalena Otrocka, Ardigen
11.05-11.35	Low molecular weight inhibitors of IL-1 β : from a 19F NMR fragment hit to a cellular proof of concept - Anna Vulpetti, Novartis
11.35-12.05	Conference Partner Presentation - Pharmaron
12.05-12.35	HiBiT CETSA for Hit Discovery in AstraZeneca: The journey to lowered hit rates and successful triage - Laura Usselman, AstraZeneca
12.35-12.50	Industry Insider - Bio-rad
12.50-14.00	Refreshment Break with Poster Session at 13.30-14.00
14.00-14.30	Leveraging morphological profiling, AI and automation as a drug discovery engine - Jordi Carreras-Puigvert, Uppsala University and Phenaros
14.30-14.40	Technology Spotlight
14.40-14.45	Technology Spotlight - Myllia Biotechnology GmbH
14.45-15.15	Platforms for the generation and high-throughput screening of cyclic peptide libraries - Cyrielle Doigneaux, Curve therapeutics
15.15-15.45	Refreshment Break
15.45-16.15	Machine learning-augmented hit prioritization and expansion - Dorota Herman, Janssen Pharmaceuticals
16.15-16.45	Discovering potent and cell-active BCL6 inhibitors through a comprehensive and integrated hit identification campaign - Rob van Montfort, ICR
16.45-17.00	Conference Close

DAY 2 - 19 OCTOBER - AUDITORIUM 2

TRANSLATING IDEAS INTO THERAPIES

19 October 2023
Auditorium 2

TRACK CHAIRS



Hitesh Sanganee
AstraZeneca



Nicky Cooper
River BioMedics

The global need for effective medicines is increasing, whilst the biology underlying new drug concepts is becoming increasingly complex, so this session will outline some of the most exciting technology advancements and approaches that have led to new therapeutics to the clinic.

The speakers will discuss what made the crucial difference but also the challenges they faced along the way. This will include successes in; AI, bifunctionals, microbiome, repurposing, gene editing and more.

08.00-09.00	Registration
09.00-10.20	All Content Streamed from Auditorium 1
10.20-11.00	Refreshment Break
11.00-11.05	Track Chair Introduction - Hitesh Sanganee, AstraZeneca and Nicky Cooper, River Biomedics
11.05-11.35	Reengineering evolution into a synthetic biology platform for novel immunotherapies - Livija Deban, Prokarium
11.35-12.05	Conference Partner Presentation - Miltenyi Biotec GmbH
12.05-12.35	Using AI for complex target product profiles through scalable precision design - Víctor Sebastián Pérez, Exscientia
12.35-12.50	Industry Insider - Revvity
12.45-14.00	Refreshment Break with Poster Session at 13.30-14.00
14.00-14.30	Translating precision in microbiome science into novel medicines - Anne Neville, Microbiotica
14.30-14.35	Technology Spotlight - Standard Biotech
14.35-14.40	Technology Spotlight - Pelago
14.40-14.45	Technology Spotlight - Ncardia
14.45-15.15	Turning an idea into a successful company - David Llewellyn, DJS Antibodies
15.15-15.45	Refreshment Break
15.45-16.15	Realizing the promise of in vivo CRISPR therapeutics - Laura Sepp-Lorenzino, Intellia Therapeutics
16.15-16.45	Single Molecule Tracking at Industrial Scale to Enable Drug Discovery - Dan Anderson, Eikon Therapeutics
16.45-17.00	Conference Close

DAY 2 - 19 OCTOBER - AUDITORIUM 3

BIOPHARMACEUTICAL DISCOVERY

19 October 2023
Auditorium 3

TRACK CHAIRS



Francisca Wollerton
AstraZeneca



Ed Coulstock
GSK

Over the years, as more and more biologics are approved (over 150 at the last count), the global market for this class of medicines is expected to be over 200 billion USD. This impact has largely been driven by recent advances in the power of antibody engineering allowing significant

improvements in the efficacy and utility of biopharma molecules. In this track, we will provide an overview of the complex and exciting world of biopharmaceutical drug discovery and survey the current state of the art of selection processes, screening and developability.

08.00-09.00	Registration
09.00-10.20	All Content Streamed from Auditorium 1
10.20-11.00	Refreshment Break
11.00-11.05	Track Chair Introduction - Francisca Wollerton, AstraZeneca and Ed Coulstock, GSK
11.05-11.35	Discovery and optimisation of therapeutic antibodies: Current technologies, successes, and challenges - Larissa Ouru, GSK
11.35-12.05	Conference Partner Presentation - Twist Bioscience
12.05-12.35	Machine Learning for Biomolecule Engineering - Anna Puskarska, AstraZeneca
12.35-12.40	Technology Spotlight - ThermoFisher
12.40-12.45	Technology Spotlight - RxCelera
12.45-12.50	Technology Spotlight - Abselion
12.50-14.00	Refreshment Break with Poster Session at 13.30-14.00
14.00-14.30	Creating enhanced biotherapeutics for oncology: The drug discovery perspective - Zahra Jawad, Creasallis
14.30-14.35	Technology Spotlight - Genedata
14.35-14.40	Technology Spotlight - Promega
14.40-14.45	Technology Spotlight - Abselion
14.45-15.15	Bicycles: An entirely new approach to targeting disease - Daniel Wing, Bicycle Therapeutics
15.15-15.45	Refreshment Break
15.45-16.15	Next-generation tetravalent bispecific antibodies for cancer immunotherapy - Katy Everett, F-star Therapeutics
16.15-16.45	Incorporating flexibility into the analytical toolbox to keep up with the challenges of new modalities - Paul Devine, AstraZeneca
16.45-17.00	Conference Close

DAY 2 - 19 OCTOBER - AUDITORIUM 4

CHEMISTRY ENABLING DRUG DISCOVERY FROM START TO CLINIC

SUPPORTED BY THE ROYAL SOCIETY OF CHEMISTRY

19 October 2023
Auditorium 4



TRACK CHAIRS



Katie Lim
RSC



Arasu Ganesan
University of East Anglia



Mary Wheldon
University of Dundee



Martin Swarbrick
Ryvu Therapeutics



Andy Merritt
LifeArc

Throughout the drug discovery process, chemistry is essential in identifying potential drug candidates, optimizing their properties, and developing effective and safe molecules to treat diseases. In this track we will hear about the impact of chemistry across all stages of drug development, from the importance of building a suitable screening deck, to the impact of synthetic methodology across the process. We explore the interface between

chemistry and biology and the impact of computational chemistry. This session is hosted by the Biological and Medicinal Chemistry Sector (BMCS) and RSC Medicinal Chemistry. The BMCS is a member-driven interest group of the Royal Society of Chemistry (RSC) which aims to further the interests of all members of the RSC, both industrial and academic, involved in the pursuit and understanding of biologically active molecules.

08.00-09.00	Registration
09.00-10.20	All Content Streamed from Auditorium 1
10.20-11.00	Refreshment Break
11.00-11.05	Track Chair Introduction - Katie Limb, Royal Society of Chemistry, Arasu Ganesan, University Of East Anglia, Mary Wheldon, University of Dundee, Martin Swarbrick, Ryvu Therapeutics and Andy Merritt, LifeArc
11.05-11.35	Progress on the promise and peril of chemical probes – tools for functional protein annotation and target validation in drug discovery - Paul Workman, Institute of Cancer
11.35-12.05	Industry Insider - Synthego
12.05-12.20	A 'direct-to-biology' platform for the rapid identification and optimisation of novel, irreversible antivirals - Harry Wilders, GSK
12.20-12.35	Development and Biological Evaluation of Novel α -Helix Mimetic Prodrugs as Leads for Prostate Cancer Treatment - Natalia Swiatek, Imperial College London
12.35-12.50	Industry Insider - Medicilon
12.50-14.00	Refreshment Break with Poster Session at 13.30-14.00
14.00-14.30	Optimisation of MSK-1/2 inhibitors leading to orally bioavailable and CNS penetrant in vivo tool compounds - Anne Valade, UCB
14.30-14.35	Technology Spotlight - Vernalis
14.35-14.40	Technology Spotlight - TBC
14.40-14.45	Technology Spotlight - TBC
14.45-15.15	Early phase process development: recent GSK examples - Alba Diaz-Rodriguez, GSK
15.15-15.45	Refreshment Break
15.45-16.15	Cell-based lead discovery and optimization of malaria preclinical and clinical candidates - Kelly Chibale, University Of Cape Town
16.15-16.45	Capability Enablement in Oral Peptide Drug Discovery: Design and Synthesis Approaches in PCSK9i Towards the Discovery of MK-0616 - Anilkumar Nair, Merck
16.45-17.00	Conference Close

DAY 2 - 19 OCTOBER - TECH THEATRE

SUSTAINIBILITY: FROM BENCH TO BEDSIDE AND BEYOND

19 October 2023
Tech Theatre

TRACK CHAIRS



Kelly Gray
AstraZeneca



James Connelly
My Green Lab

SPONSORED BY



SUSTAINIBILITY: FROM BENCH TO BEDSIDE AND BEYOND

The life sciences industry improves global health through the development and distribution of medicines, but also creates significant environmental impact. The long-term health of our planet relies on the application of innovative, sustainable scientific practices that can be applied across the drug discovery process. Through presentations, panel discussions and ECP poster highlights, this engaging and interactive sustainability track will explore principles and practises that can be embedded across drug development.

INNOVATION@ELRIG: TALKING TECHBIO – BREAKING THE ICE

Listen to the science behind four young TechBio companies followed by a Q&A session to find out how they moved from idea to commercial reality.

08.00-09.00	Registration
09.00-10.20	All Content Streamed from Auditorium 1
10.20-11.00	Refreshment Break including Hitchhiker's Guide to Accelerated Drug Discovery with AI - Join our humble effort to make a big impact in the industry!
11.00-11.05	Track Chair Introduction - Sustainability: from bench to bedside and beyond - Kelly Gray, AstraZeneca, James Connelly, My Green Lab
11.05-11.35	Lisa Ofee, Institute of Cancer Research
11.35-11.50	Anthony Holmes, NCRRs, University of Oxford and Wellcome Trust
11.50-12.05	Philippe Rocca-Serra, AstraZeneca and University of Oxford
12.05-12.20	Talia Caplan, Wellcome Trust
12.20-12.40	Sustainable Strategies for Reducing Laboratory Plastics - Ali Safavi, Grenova Inc.
12.40-14.00	Refreshment Break with Poster Session at 13.30-14.00
14.00-14.15	Fiona Adshead
14.15-14.30	Robert Williams, AstraZeneca
14.30-14.45	Martin de Kort, EATRIS
14.45-15.05	Flash Poster Presentations
15.05-15.15	Vendor Presentation
15.15-15.45	Refreshment Break
15.45-16.05	Caireen Hargreaves, AstraZeneca
16.05-16.25	Jim Bratherton, Fisher
16.25-16.40	Vendor Presentation
16.40-17.00	Conference Close

DAY 2 - 19 OCTOBER - LEARNING ZONE

EARLY CAREER PROFESSIONALS (ECP)

19 October 2023
Learning Zone

The Learning Zone is a dedicated space for our Early Career Professionals (ECP), with sessions to aid networking, career progression and flash poster presentations.

08.00-09.00	Early Career Professionals: Breakfast Meet & Greet
09.00-10.20	Auditorium content only
10.30-11.00	Science Solutions presents: Use of microfluidics for the primary screening of condensate
11.05-12.45	Auditorium content only
12.45-14.00	Flash Poster Presentations
14.00-17.00	Auditorium content only


POSTERS

With over 250 posters available for viewing Drug Discovery 2023, there is no shortage of great quality science vying for your attention.

Please take the time to have a stroll through the poster boards and drop into the flash poster presentations each lunchtime in The Learning Zone.

There are four poster awards which will be awarded on Thursday 19 October in Auditorium 1 at 10.15.

- Best General Poster
- Best Early Career Professional Poster,
- Best Vendor Poster
- Best Poster Augmenting R&D with AI



WORKSHOPS

AN EDUCATIONAL AND HANDS-ON SESSION TO TRY OUT STANDARDS IN ACTION

17 October 2023
10:00-16.00
Upper Floor Room 17

SiLA

SiLA AnIML Splash

DIVERSITY IN DRUG DISCOVERY STRATEGIES CALLS FOR DIVERSITY IN HIT FINDING APPROACHES

17 October 2023
13:00-15.00
Upper Floor Room 20

 药明康德
WuXi AppTec

WuXi AppTec

FROM TARGET ID TO CANDIDATE THERAPEUTIC: BUILDING ROBUST EARLY-STAGE DRUG DISCOVERY WORKFLOWS WITH PRECISION REPROGRAMMED HUMAN IPSC-DERIVED CELLS

18 October 2023
11:00-12:15
Upper Floor Room 23

bit.bio


bit.bio

BREAKFAST BRIEFING - THE SIGNIFICANCE OF A COMPREHENSIVE REPOSITORY FOR HIGH-QUALITY BIOSPECIMENS


19 October 2023
7:30-8:45
Upper Floor Room 23

 Drug
TARGET REVIEW

Drug Target Review



FLOOR PLAN & EXHIBITOR BOOTH LOCATIONS



Abcam	C29	BioBubble	E13
Abselion	E37	Biocair	E30
acCELLerate GmbH	E29	Biognosys AG	E38
ACROBiosystems	E40	BioIVT	B8
Agilent Technologies	B16	BioRad	B20
AM Technology	B14	BioStrata	A6
AMSBIO	C26	Biosynth Ltd	C14
Analytik Jena UK	F5	Bio-Techne	E6
ApconIX	C33	bit.bio	G1
Applied Photophysics	F30	BlackMedical and Scientific Network	E11
Aptamer	E7	BlueCatBio GmbH	F24
Araceli Bio	B1	BMG Labtech	E25
Ardigen	F12	BPS	A1
Arrayjet	E14	BrainXell	B10
Arvensis Bioscience	F23	Bruker	E3
AstraZeneca	CZ3	Caltag Medsystems	F21
Automata	E17	Cambridge Bioscience Ltd	B29
Avantor	F4	Cancer Research Horizons	F10
AXXAM S.p.A.	C5	Carterra	F15
AZoNetwork	E35	CBRE	G4
Benchling	C19	Cell Signaling Technology	E32
BIA	A7	Cellbox Solutions GmbH	F3
BGI Tech Solutions	E2	CHARLES RIVER & SAMDI Tech	F8
Bio Molecular Systems Ltd	E20	Charnwood Molecular	E5
BioAscent Discovery Ltd	D3	Codon Communications	B26

Collaborative Drug Discovery	E1	Ncardia	C12
Core Life Analytics	G3	Newcells Biotech	C28
Corning	B13	Nuclera	C3
CryoLogyx	F12b	Nuvisan ICB GmbH	F32
Cytek Biosciences	H6	Omega bio-tek	D8
Cytiva	B17	Organoids	C27
DefiniGEN Ltd	B24	Oxford Nanopore technologies	F1
DTR	H7	Peak Proteins	A8
Eurofins	C30	Peak Proteins	E27
Evotec	B9	PharmaResources	E8
faCellitate	B23	Pharmaron UK LTD	G5
Festo	F28	Porvair Sciences Ltd	B12
Fiosgenomic	C20	Promega	D4
Flexible Lab Solutions	E4	ProteinTech Europe	F27
Flow Robotics	C13	Proteome Sciences	C2
Formulatrix	D1	QINSTRUMENTS	F7
Fox Biosystems	B32	Qkine Biotechnology	B25
Fritz Gyger AG	B21	Revvity	A5
GC biotech BV	F16	Royal Society of Chemistry	CZ4
Genedata	F20	RxCelerate	C15
Gentronix	H4	SARSTEDT Limited	F25
Gifford Bioscience Limited	C32	Scale Biosciences	H5
Greiner Bio One Ltd	E33	Science Solutions Recruitment	CZ5
Grenova	B31	Scienion	E21
GSK	CZ2	Selvita	E22
Hamilton	C10	Semaron	C7
Histologix	B15	Senglobal (IBI)	A9
Horiba	D6	SGS Vitrology	C6
HUB Organoids	F31	Sino Biological	F6
Inaphaea BioLabs	B27	SLAS	F14
INNOPROT	B11	SPT Labtech	C24
INTEGRA	C1 C9	SRG	B33
Inventia	E31	Standard Bio	D7
L&M Data Science Ltd	F12a	StemCell	F29
Lablogic	C4	Stratech Scientific Ltd	E15
LGC - ATCC	E10	Synthace	C23
LifeArc	CZ1	Synthego	E12
Lightcast Discovery	E18	Takara Bio Europe SAS	B19
Malvern Panalytical	E23	Tecan	B3
MDS	F2	Thermo Fisher	C21
MedChemExpress LLC	F9	Titian	B7
Medicilon	H1	Twist	C18
Medicines Discovery Catapult	E28	UK Health Security Agency	C22
Merck	F26	UPM Biomedicals	B22
Miltenyi	E9	Vector Builder Ltd	F22
Molecular Devices	B18	Vernalis	F13
Momentum Biotechnologies	B2	WuXI AppTec	F17
Myllia Biotechnology	B28	Yokogawa Deutschland GmbH	H2
NanoLive	H8	ZEISS	F18
Nanotemper	C31	Zinsser Analytic GmbH	E36

DRUG DISCOVERY 2023 SPONSORS

CONFERENCE PARTNERS



Bit Bio
bit.bio



Twist
twistbioscience.com



BGI
bgi.com/global



Medicilon
medicilon.com



Revvity
revvity.com



AbseLion
abseLion.com



Malvern Panalytical
malvernpanalytical.com



Ncardia
ncardia.com



Selvita
selvita.com



Vernalis
vernalis.com



Lightcast Discovery
lightcast.bio



UKPGx
uk-pgx-stratmed.co.uk



BioRad
bio-rad.com



Molecular Devices
moleculardevices.com



Synthace
synthace.com



Benchling
benchling.com



Medicines Discovery Catapult
md.catapult.org.uk



Nuclera
nuclera.com



Sino Biological
sinobiological.com



Miltenyi
miltenyibiotec.com



WuXI AppTec
wuxiapptec.com



Evotec
evotec.com/en



Nanolive
nanolive.ch



Synthego
synthego.com



Genedata
genedata.com



Momentum Biotechnologies
momentum.bio



RxCelerate
rxcelerate.com



Standard BioTools
standardbio.com



Pharmaron
pharmaron.com



Yokogawa Deutschland GmbH
yokogawa.com



Horiba
horiba.com



Oxford Nanopore
Technologies
nanoporetech.com



HitGen
hitgen.com



Myllia Biotechnology
myllia.com



Scale Biosciences
scale.bio



Thermo Fisher Scientific
thermofisher.com

INDUSTRY INSIDERS

TECHNOLOGY SPOTLIGHTS

DRUG DISCOVERY 2023 SPONSORS

SUPPORTING PARTNERS



AFRO - CARIBBEAN
COMMERCIAL SCIENCE NETWORK

Afro - Caribbean Commercial
Science Network
theaccsn.com



Black Medical and Scientific Network

Black Medical and Scientific
Network



DISEASE MODEL INNOVATION

DefiniGEN
definigen.com



IPT
iptonline.com



RSK Live Science Media



SRG
srgtalent.com



Abcam
abcam.com



Engineering Chemistry

AM Technology
amt.uk



Applied Photophysics
photophysics.com



Arrayjet
arrayjet.com



AXXAM
axxam.com



AstraZeneca
astrazeneca.co.uk



BPS
bps.ac.uk



Drug Target Review
drugtargetreview.com



LifeArc
lifearc.org



Science Solutions Recruitment
sciencesolutionsrecruitment.com



Technology Networks
technologynetworks.com



acCELLerate
accelerate.me



AMS BIO
amsbio.com



Aptamer Group
aptamergroup.com



Arvensis Bioscience
arvensis.uk



Bio Molecular Systems
biomolecularsystems.com



AZoNetwork
azonetwork.com



Cancer Research Horizons
cancerresearchhorizons.com



EBR
europeanpharmaceuticalreview.com



MSD
msd.com



Senglobal (IBI)
senglobalcoms.com



The BioIndustry Association
bioindustry.org



ACROBiosystems
acrobiosystems.com



Analytik Jena
analytik-jena.com



Araceli Bio
aracelibio.com



Automata
automata.tech



BioAscent Discovery
bioascent.com



BioStrata
biostratamarketing.com



Codon Communications
codoncommunications.com



GSK
gsk.com/en-gb



Royal Society of Chemistry
rsc.org



SLAS
slas.org



Agilent Technologies
agilent.com



Apconix
apconix.com



Ardigen
ardigen.com



Avantor
avantorsciences.com



bioBUBBLE
biobubble.com

PARTNERS

DRUG DISCOVERY 2023 SPONSORS

PARTNERS



MOVING SCIENCE FORWARD

Biocair
biocair.com



Bio-Techne
bio-techne.com



Bruker
bruker.com/en.html



Carterra
carterra-bio.com



Charnwood Molecular
charnwooddiscovery.com



Cancer Research UK
cancerresearchuk.org



Eurofins Pharma Discovery Services

Eurofins
eurofins.com



Flexible Lab Solutions
flexible-lab-solutions.co.uk



Fritz Gyger
fgyger.ch



Greiner Bio One
gbo.com



HUB Organoids
horiba.com



Biognosys
biognosys.com



BLUE CAT BIO

BlueCatBio
bluecatbio.com



Caltag Medsystems
caltagmedsystems.co.uk



CBRE
cbre.co.uk



Collaborative Drug Discovery
collaborativedrug.com



CryoLogyx
cryologyx.com



faCellitate
facellitate.com



Flow Robotics
flow-robotics.com



GC biotech
gcbiotech.com



Grenova
grenovasolutions.com



Inaphaea BioLabs
inaphaea.com



BioIVT
bioivt.com



BMG Labtech
bmglabtech.com



Cambridge Bioscience
bioscience.co.uk



Cell Signaling Technology
cellsignal.com



Core Life Analytics
corelifeanalytics.com



Cytek Biosciences
cytekbio.com



Festo
festo.com



Formulatrix
formulatrix.com



Gentronix
gentronix.co.uk



Hamilton
hamiltoncompany.com



INNOPROT
innoprot.com



Biosynth
biosynth.com



BrainXell
brainxell.com



Carl Zeiss Limited
zeiss.co.uk



Cellbox Solutions
cellbox-solutions.com



Corning
corning.com/worldwide/en.html



Cytiva
cytivalifesciences.com



Fios Genomics
fiosgenomics.com



Fox Biosystems
foxbiosystems.com



Gifford Bioscience
giffordbioscience.com



Histologix
histologix.com



INTEGRA
integra-biosciences.com

DRUG DISCOVERY 2023 SPONSORS

PARTNERS

INVENTIA
LIFE SCIENCE

Inventia
inventia.life

MCE
MedChemExpress

MedChemExpress
medchemexpress.com

NEWCELLS

Newcells Biotech
newcellsbiotech.co.uk

PELAGO
BIOSCIENCE

Pelago Bioscience
pelagobio.com

PROTEINTECH
Antibodies | ELISA kits | Proteins

ProteinTech Europe
ptglab.com

samdi
tech inc.
a charles river company

SAMDI Tech
samditech.com

SGS

SGS Vitrology
sgs.com

Stratech

Stratech Scientific
stratech.co.uk

UK Health Security Agency

UK Health Security Agency

L&M
DATA SCIENCE

L&M Data Science
lmdatascience.com

MERCK

Merck
merckgroup.com

NUVISAN

Nuvisan
nuvisan.com/home.html

Pharma Resources

PharmaResources
pha-res.com

PROTEOME
sciences

Proteome Sciences
proteomics.com

SARSTEDT

SARSTEDT
sarstedt.com/en

SILA

SILA
sila-standard.com

TAKARA

Takara Bio
takarabio.com

UPM

UPM Biomedicals
upmbiomedicals.com

LabLogic

Lablogic
lablogic.com

MOLGEN

MolGen
molgen.com

OMEGA
BIO-TEK
innovations in nucleic acid isolation

Omega bio-tek
omegabiotek.com

porvair
sciences

Porvair Sciences
porvairsciences.com

QINSTRUMENTS

QINSTRUMENTS
qinstruments.com

scienion
A CELLINK COMPANY

Scienion
scienion.com

sptlabtech

SPT Labtech
sptlabtech.com

TECAN

Tecan
tecan.com

VectorBuilder.com

Vector Builder
en.vectorbuilder.com

ATCC **LGC**

LGC - ATCC
atcc.org | lgcstandards.com

NANO
TEMPER

NanoTemper Technologies
nanotempertech.com

PEAK
PROTEINS

Peak Proteins
peakproteins.com

Promega

Promega
promega.co.uk

Qkine

Qkine Biotechnology
qkine.com

semarion

Semarion
semarion.com

STEMCELL
TECHNOLOGIES

StemCell
stemcell.com

titian

Titian
titancompany.in

ZINSSER
ANALYTIC
An Ingersoll Rand Business

Zinsser Analytic
zinsser-analytic.com

ABOUT ELRIG

The European Laboratory Research & Innovation Group (ELRIG) is a leading European not-for-profit organization that exists to provide outstanding scientific content to the life science community. The foundation of the organization is based on the use and application of automation, robotics and instrumentation in life science laboratories, but over time, we have evolved to respond to the needs of biopharma by developing scientific programmes that focus on cutting-edge research areas that have the potential to revolutionize drug discovery.

Comprising a global community of over 12,000 life science professionals, participating in our events, whether it be at one of our scientific conferences or one of our networking meetings, will enable any of our community to exchange information, within disciplines and across academic and biopharmaceutical organisations, on an open access basis, as all our events are free-of-charge to attend!

STRATEGIC PILLARS



EVENTS

- World-class scientific events
- Topical, relevant content
- Free to attend



EQUALITY, DIVERSITY & INCLUSIVITY

- Accessible to all
- Promotes engagement and collaboration
- Encourages diversity



PRESENCE & AWARENESS

- Build a trusted brand
- Work with communities
- Expand our digital presence



SUSTAINABILITY

- A transparent organisation
- Operational excellence
- Becoming a sustainable events organiser

FEBRUARY

Careers Webinar
21 February

MARCH

Metabolic Disease Forum
Copenhagen, DK
March

Research & Innovation 2024
Manchester, UK
20 – 21 March

APRIL

AI in Drug Discovery Forum
Cambridge, UK
25 April

Careers Webinar
25 April

MAY

Pint of Science Networking Events
Various, Europe
13 – 15 May

Advances in cell-based screening in drug discovery 2024
Gothenburg, SE
15 – 16 May

JUNE/JULY

Drug Discovery Germany Forum
Frankfurt, DE
June

ELRIG's Summer Social
Cambridge, UK
3 July

SEPTEMBER

Drug Discovery Scotland Forum
Edinburgh, UK
September

ECP Networking Event
Oxford, UK
10 September

OCTOBER

Drug Discovery 2024
London, UK
2 – 3 October

NOVEMBER

Protein Sciences in Drug Discovery
Cambridge, UK
4 – 5 November

DECEMBER

ELRIG – SLAS Joint Networking Event
Paris, FR
December